The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
- Conditions
- Non-Hodgkin Lymphoma
- Registration Number
- NCT02736357
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000 non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic, tumor, and treatment factors, as well as the interaction among these factors, on short and long-term outcomes. These efforts will identify new approaches to improve the survival and well-being of NHL patients.
- Detailed Description
Newly diagnosed non-Hodgkin lymphoma (NHL) patients will be recruited from each center participating in the LEO cohort. At time of consent, participants will be asked to completed several questionnaires collecting health history, current medical and quality of life questions. Patients will also provide a baseline blood sample that will processed locally and stored centrally for future research use. Additionally, consent is given for use of excess clinical tumor tissue for research use.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment
- Patients may have been treated as long as initial NHL diagnosis is within 6 months of enrollment
- 18 years of age or older
- Lymphoma diagnosis greater than 184 days from date of consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Short (<5 years), medium (5-10 years), and long-term (>10 years) Time from date of diagnosis to date of death
- Secondary Outcome Measures
Name Time Method Event Free Survival (EFS) Short (<5 years), medium (5-10 years), and long-term (>10 years) Time from date of diagnosis to date of first defined event (disease progression, relapse or re-treatment for lymphoma, or death)
Lymphoma Specific Survival (LSS) Short (<5 years), medium (5-10 years), and long-term (>10 years) Time from date of diagnosis to date of death due to lymphoma
Trial Locations
- Locations (8)
Weill Cornell Medical College
🇺🇸New York, New York, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
University of Miami
🇺🇸Miami, Florida, United States
Emory University
🇺🇸Atlanta, Georgia, United States
University of Iowa
🇺🇸Iowa City, Iowa, United States
Washington University
🇺🇸Saint Louis, Missouri, United States
University of Rochester
🇺🇸Rochester, New York, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States